Evaluation Platforms for SARS-CoV-2 Drugs
Creative Biolabs is always dedicated to assisting our clients with the most satisfactory drug discovery related services. In response to the increasingly severe SARS-CoV-2 infection situation, we can not only provide super high-quality data but also help you establish a proteomics research pipeline and create new techniques for your projects.
Reverse genetics systems are capable of generating specific viruses, including coronavirus, which have been applied in target screening and drug discovery. Furthermore, reverse genetics systems are critical to studying the lifecycle of different viruses without a large-scale containment laboratory. Equipped with a team of professional scientists, we have generated a number of reverse genetics systems for our clients to study life cycle, replication, transcription, and pathophysiology of SARS-CoV-2. Targeted RNA recombination of SARS-CoV-2 can be a multifunctional, powerful tool for analyzing the SARS-CoV-2 genome and genetic mutations in different evolutionary time-scales.
Creative Biolabs has developed a series of cell lines for COVID-19 research, including ACE2-enhanced or knockout (KO) cell lines, TMPRSS2-enhanced or knockout (KO) cell lines, and so on.
Pseudoviruses do not contain viral nucleic acids and cannot be replicated in the human body, but contain the necessary components for viral infection and entry into cells. Therefore, they can be used as an effective replacement of live viruses to assess the neutralizing activity of drugs or vaccines under the premise of ensuring safety. Creative Biolabs packages a pseudovirus with the SARS-CoV-2 spike protein on the surface and a luciferase reporter gene inside, and uses the proprietary ACE2-CHO Clonal Cell-expressing the ACE-2 receptor as the target cell, which can effectively assess the neutralizing activity of the COVID-19 vaccine or drug.
The main protease of SARS-CoV-2 is considered to be essential for viral replication and therefore is considered a promising target for COVID-19 antiviral therapy. To find and validate potent inhibitors for SARS-CoV-2 protease, Creative Biolabs provides protease assay service to help speed up the development of therapeutics to conquer COVID-19, including pseudovirus neutralization assay, FRET-based assay, FRET-based assay, thermal shift binding assay, counter screening assays, cellular cytotoxicity test, viral yield reduction (VYR) assay, CPE assay, and differential scanning fluorimetry.
Animal models provide an important tool to investigate how diseases affect animals/humans and thus help decide to take potential therapies from preclinical studies to humans. As a world-leading service provider in preclinical drug discovery, Creative Biolabs is capable of offering high-quality animal model development services to accelerate the drug discovery process for the treatment of coronavirus infection. Based on our advanced disease model platform, our professional scientists are willing to assist you in developing the most appropriate drug candidate for your research.
Creative Biolabs offers various animal models, such as mice, rats, dogs, and transgenic mice, to overcome the hurdle for investigating the cytokine and chemokine responses of SARS-CoV-2. Additionally, we have also established a panel of pre-qualified cytokine and chemokine assays to avoid a number of additional diseases, including acute lung injury (ALI), and acute respiratory distress syndrome (ARDS), caused by SARS-CoV-2 targeted new drugs.
If you are interested in our services, please do not hesitate to contact us for more information.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.